The price of Neogenomics Inc. (NASDAQ: NEO) closed at $14.87 in the last session, up 0.41% from day before closing price of $14.81. In other words, the price has increased by $+0.06 from its previous closing price. On the day, 617139 shares were traded.
Ratios:
We take a closer look at NEO’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 5.95 and its Current Ratio is at 6.20. In the meantime, Its Debt-to-Equity ratio is 0.65 whereas as Long-Term Debt/Eq ratio is at 0.64.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on December 29, 2023, Reiterated its Buy rating but revised its target price to $21 from $25 previously.
On August 21, 2023, Stephens Upgraded its rating to Overweight which previously was Equal-Weight but kept the price unchanged to $18.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 04 ’24 when TETRAULT LYNN A. sold 6,112 shares for $15.97 per share. The transaction valued at 97,579 led to the insider holds 50,062 shares of the business.
Olivo Alicia C sold 2,587 shares of NEO for $38,713 on Feb 15 ’24. The General Counsel now owns 34,866 shares after completing the transaction at $14.96 per share. On Nov 17 ’23, another insider, Olivo Alicia C, who serves as the General Counsel of the company, sold 2,669 shares for $18.39 each. As a result, the insider received 49,083 and left with 37,140 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NEO now has a Market Capitalization of 1.89B and an Enterprise Value of 2.09B. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.21 while its Price-to-Book (P/B) ratio in mrq is 2.01. Its current Enterprise Value per Revenue stands at 3.52 whereas that against EBITDA is -118.42.
Stock Price History:
Over the past 52 weeks, NEO has reached a high of $21.22, while it has fallen to a 52-week low of $11.03. The 50-Day Moving Average of the stock is 15.27, while the 200-Day Moving Average is calculated to be 15.60.
Shares Statistics:
According to the various share statistics, NEO traded on average about 944.38K shares per day over the past 3-months and 658.45k shares per day over the past 10 days. A total of 127.37M shares are outstanding, with a floating share count of 126.12M. Insiders hold about 1.16% of the company’s shares, while institutions hold 99.27% stake in the company. Shares short for NEO as of Mar 15, 2024 were 7.29M with a Short Ratio of 7.72, compared to 7.45M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 5.71% and a Short% of Float of 8.06%.
Earnings Estimates
The company has 11 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.05 for the current quarter, with a high estimate of -$0.02 and a low estimate of -$0.11, while EPS last year was -$0.09. The consensus estimate for the next quarter is -$0.01, with high estimates of $0.01 and low estimates of -$0.06.
Analysts are recommending an EPS of between $0.08 and -$0.19 for the fiscal current year, implying an average EPS of -$0.01. EPS for the following year is $0.14, with 12 analysts recommending between $0.2 and $0.06.
Revenue Estimates
According to 12 analysts, the current quarter’s revenue is expected to be $149.89M. It ranges from a high estimate of $152M to a low estimate of $148.1M. As of the current estimate, Neogenomics Inc.’s year-ago sales were $137.22M, an estimated increase of 9.20% from the year-ago figure. For the next quarter, 12 analysts are estimating revenue of $162.65M, an increase of 18.40% over than the figure of $9.20% in the same quarter last year. There is a high estimate of $164.22M for the next quarter, whereas the lowest estimate is $161.1M.
A total of 13 analysts have provided revenue estimates for NEO’s current fiscal year. The highest revenue estimate was $659M, while the lowest revenue estimate was $651M, resulting in an average revenue estimate of $654.56M. In the same quarter a year ago, actual revenue was $591.64M, up 10.60% from the average estimate. Based on 12 analysts’ estimates, the company’s revenue will be $718.47M in the next fiscal year. The high estimate is $727.08M and the low estimate is $707.1M. The average revenue growth estimate for next year is up 9.80% from the average revenue estimate for this year.
